US OptionsDetailed Quotes
ATRC250117C17500
- 9.40
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
9.40Open9.40Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover0.00%IV-14.36%PremiumJan 17, 2025Expiry Date13.91Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.29Leverage Ratio--Theta--Rho--Eff Leverage--Vega
AtriCure Stock Discussion
Sign in to post a comment
$Garmin (GRMN.US)$ $AtriCure (ATRC.US)$ $Vast Renewables (VSTE.US)$ $ASP Isotopes (ASPI.US)$ $Unisys (UIS.US)$ $Solidion Technology (STI.US)$ $NerdWallet (NRDS.US)$ $Xilio Therapeutics (XLO.US)$ $Cryo-Cell International (CCEL.US)$ $Omnicell (OMCL.US)$ $Reddit (RDDT.US)$ $Ensysce Biosciences (ENSC.US)$ $Tharimmune (THAR.US)$
5
1
1
$SeaStar Medical (ICU.US)$ $Direxion Daily GOOGL Bull 2X Shares (GGLL.US)$ $Torrid (CURV.US)$ $Snap Inc (SNAP.US)$ $60 Degrees Pharmaceuticals (SXTP.US)$ $GlycoMimetics (GLYC.US)$ $Mirion (MIR.US)$ $AtriCure (ATRC.US)$ $Reddit (RDDT.US)$ $Magic Empire Global (MEGL.US)$ $Sky Quarry (SKYQ.US)$ $Enovix (ENVX.US)$ $NerdWallet (NRDS.US)$ $Starbox Group (STBX.US)$
📊⚡️📊
📊⚡️📊
4
Insider transactions at AtriCure are not encouraging. However, insiders' share ownership suggests some alignment. Maggie Yuen's sale at a price above the current share price may not reflect insider confidence.
Investors forecast sustained strong revenue performance from AtriCure, reflected in a high P/S ratio. Shareholders currently show confidence in the company's future revenue, bolstering its shares. The high P/S ratio is deemed appropriate due to robust future revenues.
The lack of insider purchasing and ample selling in the past year could be red flags for potential investors in AtriCure. Despite high insider ownership, absence of buying is unsettling. Additionally, unspecified risks and concerns for AtriCure are noteworthy.
No comment yet
Den the Dragon :
